Aclipse has successfully conducted the US FDA pre-IND meeting for M102

Aclipse Therapeutics Expands Drug Development Pipeline

Aclipse Therapeutics Expands Drug Development Pipeline with Signing of Exclusive, Worldwide License Agreement with Chong Kun Dang Pharmaceutical Corporation to

September 14, 2023

Aclipse Therapeutics receives a therapeutic development award of $1.475 million

Aclipse Therapeutics and its subsidiary Aclipse One Inc (“Aclipse” or “the Company”), an innovative biopharmaceutical company, today announced that the

April 20, 2022

CEOCFO Magazine Interviewed Aclipse Therapeutics CEO Raymond Houck

CEOCFO Magazine has interviewed Aclipse Therapeutics CEO Raymond Houck. Mr. Houck has introduced the background of the company and our

March 11, 2021

Aclipse Therapeutics Announces $2.2 Million Grant from UK’s Medical Research Council for Development of M102

Funding Supports Aclipse Therapeutics’ and Sheffield Institute of Translational Neuroscience’s Development of M102 in Amyotrophic Lateral Sclerosis Radnor, PA —

February 8, 2021

February 16, 2020

Aclipse Therapeutics has successfully conducted the US FDA pre-IND meeting for M102. The FDA has reviewed the M102 preclinical data package and confirmed the necessary preclinical studies for M102 to initiate its first-in-human studies. The agency has also provided valuable guidance to support the clinical development of M102.

Learn more